Definium Therapeutics is a late-stage clinical biopharmaceutical company focused on developing accessible treatments for psychiatric and neurological disorders using psychedelics. Our mission is to forge a new era of psychiatry by applying scientific rigor to psychedelics. Our lead product candidate, lysergide tartrate, is in development for generalized anxiety, major depressive disorder, and posttraumatic stress disorder. Our pipeline also includes DT402 for the core symptoms of autism spectrum disorder. We aim to change the trajectory of mental health care by addressing the underlying causes of these disorders. Headquartered in New York, Definium Therapeutics trades on Nasdaq under the symbol DFTX. This is a high-impact, foundational leadership role reporting to the VP of Sales. The Sr. Director will own the end-to-end strategy and execution of sales training and capability development for a novel CNS product. This role requires deep scientific fluency, nuanced patient and HCP engagement, and rigorous compliance. The individual will shape how the sales organization and adjacent commercial field teams master the science, patient journey, competitive differentiation, and unique considerations of bringing a novel psychedelic therapy to market. Success will directly influence launch readiness, field force excellence, and long-term commercial performance.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Director